GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » EPS (Diluted)

WuXi Biologics (Cayman) (FRA:1FW2) EPS (Diluted) : €0.10 (TTM As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) EPS (Diluted)?

WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the six months ended in Jun. 2023 was €0.07. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.10.

WuXi Biologics (Cayman)'s EPS (Basic) for the six months ended in Jun. 2023 was €0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.11.

WuXi Biologics (Cayman)'s EPS without NRI for the six months ended in Jun. 2023 was €0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was €0.12.

During the past 12 months, WuXi Biologics (Cayman)'s average EPS without NRIGrowth Rate was 4.70% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 55.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 55.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average EPS without NRI Growth Rate was 138.10% per year. The lowest was 49.30% per year. And the median was 59.60% per year.


WuXi Biologics (Cayman) EPS (Diluted) Historical Data

The historical data trend for WuXi Biologics (Cayman)'s EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) EPS (Diluted) Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.05 0.11 0.14 0.10

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.08 0.06 0.07 0.03

Competitive Comparison of WuXi Biologics (Cayman)'s EPS (Diluted)

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PE Ratio distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s PE Ratio falls into.



WuXi Biologics (Cayman) EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

WuXi Biologics (Cayman)'s Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(598.527-0)/4375.908
=0.14

WuXi Biologics (Cayman)'s Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(292.141-0)/4349.846
=0.07

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (FRA:1FW2) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


WuXi Biologics (Cayman) EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines